Amicus Therapeutics [FOLD] vs Praxis Precision [PRAX] Detailed Stock Comparison

Amicus Therapeutics Inc.

NASDAQ
Loading...

Praxis Precision Medicines Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Amicus Therapeutics Inc. wins in 9 metrics, Praxis Precision Medicines Inc. wins in 5 metrics, with 0 ties. Amicus Therapeutics Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Amicus Therapeutics Inc. Praxis Precision Medicines Inc. Better
Price-to-Book Ratio 16.40 9.46 Praxis Precision Medicines Inc.
Debt-to-Equity Ratio 161.30 0.01 Praxis Precision Medicines Inc.
PEG Ratio 17.66 -38.31 Amicus Therapeutics Inc.
EV/EBITDA 111.78 -26.32 Amicus Therapeutics Inc.
Profit Margin (TTM) -4.28% 0.00% Praxis Precision Medicines Inc.
Operating Margin (TTM) 8.61% 0.00% Amicus Therapeutics Inc.
EBITDA Margin (TTM) 8.61% N/A N/A
Return on Equity -11.58% -45.83% Amicus Therapeutics Inc.
Return on Assets (TTM) 2.49% -28.69% Amicus Therapeutics Inc.
Free Cash Flow (TTM) $29.85M $-249.12M Amicus Therapeutics Inc.
1-Year Return 117.24% 807.83% Praxis Precision Medicines Inc.
Price-to-Sales Ratio (TTM) 7.16 N/A N/A
Enterprise Value $4.69B $8.58B Praxis Precision Medicines Inc.
EV/Revenue Ratio 7.39 N/A N/A
Gross Profit Margin (TTM) 85.67% N/A N/A
Revenue per Share (TTM) $2 N/A N/A
Earnings per Share (Diluted) $-0.09 $-13.48 Amicus Therapeutics Inc.
Beta (Stock Volatility) 0.48 2.97 Amicus Therapeutics Inc.
Short % of Float 6.77% 14.21% Amicus Therapeutics Inc.

Amicus Therapeutics Inc. vs Praxis Precision Medicines Inc. Stock Performance Analysis

Loading Price Chart...

FOLD
PRAX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Amicus Therapeutics Inc.0.00%0.21%0.56%1.40%63.18%1.54%
Praxis Precision Medicines Inc.8.08%-21.90%-17.38%-12.35%49.84%-2.61%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Amicus Therapeutics Inc.117.24%19.26%48.62%125.00%99.31%7.33%
Praxis Precision Medicines Inc.807.83%2,210.03%21.08%-16.07%-16.07%-16.07%

Performance & Financial Health Analysis: Amicus Therapeutics Inc. vs Praxis Precision Medicines Inc.

MetricFOLDPRAX
Market Information
Market Cap i$4.54B$9.60B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i2,548,496391,453
90 Day Avg. Volume i3,188,995416,321
Last Close$14.49$278.93
52 Week Range$5.51 - $14.50$37.19 - $366.52
% from 52W High-0.07%-23.90%
All-Time High$25.39 (Dec 21, 2020)$914.27 (Jan 04, 2021)
% from All-Time High-42.93%-69.49%
Growth Metrics
Quarterly Revenue Growth0.24%N/A
Quarterly Earnings Growth-0.89%-1.00%
Financial Health
Profit Margin (TTM) i-0.04%0.00%
Operating Margin (TTM) i0.09%0.00%
Return on Equity (TTM) i-0.12%-0.46%
Debt to Equity (MRQ) i161.300.01
Cash & Liquidity
Book Value per Share (MRQ)$0.88$34.85
Cash per Share (MRQ)$0.94$21.52
Operating Cash Flow (TTM) i$33.15M$-249,068,000
Levered Free Cash Flow (TTM) i$47.84M$-146,253,744
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Amicus Therapeutics Inc. vs Praxis Precision Medicines Inc.

MetricFOLD (Apr 24, 2026)PRAX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) iN/AN/A
Forward P/E i17.66-38.31
PEG Ratio i17.66-38.31
Price to Sales (TTM) i7.16N/A
Price to Book (MRQ) i16.409.46
Market Capitalization
Market Capitalization i$4.54B$9.60B
Enterprise Value i$4.69B$8.58B
Enterprise Value Metrics
Enterprise to Revenue i7.39N/A
Enterprise to EBITDA i111.78-26.32
Risk & Other Metrics
Beta i0.482.97
Book Value per Share (MRQ) i$0.88$34.85

Financial Statements Comparison: Amicus Therapeutics Inc. vs Praxis Precision Medicines Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricFOLD (2025)PRAX (2025)
Revenue/Sales i634.21M0
Cost of Goods Sold i72.93MN/A
COGS % of Revenue i11.5%-
Gross Profit i561.28MN/A
Gross Margin i88.5%-
Research & Development i135.84M267.12M
Operating Income (EBIT) i34.49M-326.20M
Operating Margin i5.4%-
EBITDA i55.51M-326.06M
EBITDA Margin i8.8%-
Pre-Tax Income i191,000-303.27M
Pre-Tax Income % of Revenue i0.0%-
Income Tax i27.30MN/A
Income Tax % of Revenue i4.3%-
Net Income (Profit) i-27.11M-303.27M
Profit Margin i-4.3%-

Balance Sheet & Liquidity Metrics

MetricFOLD (2025)PRAX (2025)
Cash & Equivalents i214.01M357.33M
Total Current Assets i676.17M610.91M
Total Current Assets % of Revenue i106.6%-
Total Current Liabilities i237.83M59.77M
Total Current Liabilities % of Revenue i37.5%-
Long-Term Debt i433.62M0
Long-Term Debt % of Revenue i68.4%-
Total Shareholders Equity i274.24M878.14M
Retained Earnings i-2.77B-1.14B
Retained Earnings % of Revenue i-436.3%-
Property, Plant & Equipment i36.91M415,000

Cash Flow Statement Comparison

MetricFOLD (2025)PRAX (2025)
Operating Cash Flow i32.08M-257.32M
Operating Cash Flow % of Revenue i5.1%-
Capital Expenditures iN/A-56,000
Free Cash Flow i29.85M-249.12M
FCF Margin i4.7%-
Debt Repayment i-272,000N/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricFOLDPRAX
Shares Short i21.10M3.95M
Short Ratio i5.589.07
Short % of Float i6.77%14.21%
Shares Outstanding i310.85M25.20M
Float Shares i311.44M25.78M
% Held by Insiders i0.69%0.40%
% Held by Institutions i104.35%106.12%
% Held by Public i-5.04%-6.52%

Dividend Analysis & Yield Comparison: Amicus Therapeutics Inc. vs Praxis Precision Medicines Inc.

MetricFOLDPRAX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A